Breaking News Instant updates and real-time market news.

FPRX

Five Prime

$6.12

0.01 (0.16%)

, GOSS

Gossamer Bio

$18.52

0.82 (4.63%)

16:11
06/09/19
06/09
16:11
06/09/19
16:11

Five Prime announces departure of Sheila Gujrathi From Board of Directors

Five Prime (FPRX) announced the departure of Sheila Gujrathi from the company's board of directors. Gujrathi has served as a board member of Five Prime since December 2015 and is stepping down from the board to focus on her role as President and Chief Executive Officer of Gossamer Bio (GOSS).

FPRX

Five Prime

$6.12

0.01 (0.16%)

GOSS

Gossamer Bio

$18.52

0.82 (4.63%)

  • 10

    Jun

FPRX Five Prime
$6.12

0.01 (0.16%)

05/28/19
ROTH
05/28/19
INITIATION
Target $10
ROTH
Neutral
Five Prime initiated with a Neutral at Roth Capital
Roth Capital analyst Tony Butler initiated Five Prime initiated with a Neutral and $10 price target.
05/28/19
ROTH
05/28/19
INITIATION
Target $10
ROTH
Neutral
Five Prime initiated with a Neutral at Roth Capital
Roth Capital analyst Tony Butler initiated Five Prime with a Neutral rating and a price target of $10. The analyst is positive on the company's "robust protein therapeutics platform" with additional upside potentially coming from its expected clinical updates from two early stage programs, also noting that the recent profitability efforts could also make it an "appealing M&A target". Butler warns however that "significant overhang" exists over Five Prime's lead Bemarituzumab program.
06/03/19
WELS
06/03/19
DOWNGRADE
Target $10
WELS
Market Perform
Five Prime downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo Securities analyst Jim Birchenough downgraded Five Prime Therapeutics to Market Perform from Outperform and lowered his price target for the shares to $10 from $35.
06/03/19
06/03/19
DOWNGRADE
Target $10

Market Perform
Five Prime downgraded to Market Perform following ASCO data at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough downgraded Five Prime Therapeutics to Market Perform from Outperform following review of data at ASCO for B7:H4 antibody FPA-150 in B7:H4+ patients with solid tumors including ovarian cancer. The analyst says overall response rate of 1/18 in B7:H4+ tumors was "underwhelming," with lack of clarity on dose response. Birchenough also lowered his price target on the shares to $10 from $35.
GOSS Gossamer Bio
$18.52

0.82 (4.63%)

03/05/19
LEHM
03/05/19
INITIATION
Target $27
LEHM
Overweight
Gossamer Bio initiated with an Overweight at Barclays
Barclays analyst Geoff Meacham started Gossamer Bio with an Overweight rating and $27 price target. The companys lead assets are differentiated and could bring a new mechanism of action to the categories of immunology, inflammation, and oncology, Meacham tells investors in a research note. GB001 is the primary value driver for Gossamer as it offers a " "compelling opportunity" for an oral agent in the severe asthma market, says the analyst. He sees $2B-plus in peak sales potential for GB001 in the eosinophilic asthma market and looks for interim Phase 2 data in the first half of 2020 "as a major de-risking event."
03/05/19
LEER
03/05/19
INITIATION
Target $30
LEER
Outperform
Gossamer Bio initiated with an Outperform at SVB Leerink
SVB Leerink analyst Joseph Schwartz started coverage of Gossamer Bio with an Outperform rating and $30 price target. The analyst believes the novel mechanisms being pursued by the company could offer disease modifying activity in major markets, which offer significant room for clinical improvement.
03/05/19
EVER
03/05/19
INITIATION
Target $30
EVER
Outperform
Gossamer Bio initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Gossamer with an Outperform and $30 price target saying it continues to build on its compelling pipeline targeting allergic diseases, PAH, IBD and oncology.
03/05/19
03/05/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) initiated with a Buy at Needham. 2. Lennox (LII) initiated with a Neutral at Goldman Sachs. 3. Aurora Cannabis (ACB) initiated with an Outperform at Cowen. 4. Floor & Decor (FND) initiated with an Outperform at Baird. 5. Gossamer Bio (GOSS) initiated with an Outperform at Evercore ISI and SVB Leerink, an Overweight at Barclays, and a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

CDEV

Centennial Resource Development

$3.42

0.09 (2.70%)

07:22
10/17/19
10/17
07:22
10/17/19
07:22
Hot Stocks
Centennial Resource Development appoints Steven Shapiro to board of directors »

Centennial Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

CAKE

Cheesecake Factory

$38.41

0.06 (0.16%)

07:21
10/17/19
10/17
07:21
10/17/19
07:21
Downgrade
Cheesecake Factory rating change  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 04

    Nov

  • 12

    Nov

NFLX

Netflix

$286.83

2.59 (0.91%)

07:20
10/17/19
10/17
07:20
10/17/19
07:20
Recommendations
Netflix analyst commentary  »

Netflix guidance adds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

AKG

Asanko Gold

$0.90

-0.0083 (-0.91%)

, GFI

Gold Fields

$5.52

0.15 (2.79%)

07:19
10/17/19
10/17
07:19
10/17/19
07:19
Hot Stocks
Asanko Gold reports Q3 AGM gold production of 62,440 ounces »

Asanko Gold (AKG)…

AKG

Asanko Gold

$0.90

-0.0083 (-0.91%)

GFI

Gold Fields

$5.52

0.15 (2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$286.83

2.59 (0.91%)

07:17
10/17/19
10/17
07:17
10/17/19
07:17
Recommendations
Netflix analyst commentary  »

Stifel keeps Buy rating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

OLN

Olin

$18.25

-0.015 (-0.08%)

, WLK

Westlake Chemical

$62.28

-0.24 (-0.38%)

07:17
10/17/19
10/17
07:17
10/17/19
07:17
Downgrade
Olin, Westlake Chemical rating change  »

JPMorgan downgrades Olin…

OLN

Olin

$18.25

-0.015 (-0.08%)

WLK

Westlake Chemical

$62.28

-0.24 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 05

    Nov

NURO

NeuroMetrix

$0.32

-0.0249 (-7.21%)

07:15
10/17/19
10/17
07:15
10/17/19
07:15
Earnings
NeuroMetrix reports Q3 revenue $2.1M, one estimate $3.93M »

"A new commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 12

    Nov

NFLX

Netflix

$286.83

2.59 (0.91%)

07:13
10/17/19
10/17
07:13
10/17/19
07:13
Recommendations
Netflix analyst commentary  »

Netflix's Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

CMA

Comerica

$65.50

-1.505 (-2.25%)

07:13
10/17/19
10/17
07:13
10/17/19
07:13
Downgrade
Comerica rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCBI

Texas Capital

$54.33

-0.15 (-0.28%)

07:12
10/17/19
10/17
07:12
10/17/19
07:12
Recommendations
Texas Capital analyst commentary  »

Texas Capital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$79.12

0.8 (1.02%)

07:11
10/17/19
10/17
07:11
10/17/19
07:11
Hot Stocks
Philip Morris backs FY19 currency-neutral net revenue growth of at least 6% »

Lowers FY19 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

GOLD

Barrick Gold

$16.95

0.3 (1.80%)

07:11
10/17/19
10/17
07:11
10/17/19
07:11
Hot Stocks
Barrick Gold sees FY production towards upper end of 5.1M-5.6M ounce guidance »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

PFE

Pfizer

$36.34

-0.17 (-0.47%)

07:10
10/17/19
10/17
07:10
10/17/19
07:10
Initiation
Pfizer initiated  »

Pfizer reinstated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

MAIN

Main Street

$42.08

0.155 (0.37%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Earnings
Main Street declares semi-annual supplemental cash dividend of 24c in December »

Main Street declared its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

POOL

Pool Corp.

$200.56

-4.63 (-2.26%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Earnings
Pool Corp. raises FY19 EPS view $6.20-$6.40 from $6.09-$6.34 

Consensus $6.22.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

PM

Philip Morris

$79.12

0.8 (1.02%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Hot Stocks
Philip Morris revises FY19 shipment volume assumption to "down 1% - down 1.5" »

Prior guidance was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AZN

AstraZeneca

$43.80

-0.41 (-0.93%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Hot Stocks
AstraZeneca says trastuzumab deruxtecan granted FDA Priority Review »

AstraZeneca and Daiichi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

POOL

Pool Corp.

$200.56

-4.63 (-2.26%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Earnings
Pool Corp. reports Q3 EPS ex-items $1.84, consensus $1.78 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

TXMD

TherapeuticsMD

$3.70

-0.22 (-5.61%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Initiation
TherapeuticsMD initiated  »

TherapeuticsMD initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$79.12

0.8 (1.02%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Earnings
Philip Morris lowers FY19 EPS view to 'at least $4.73' from 'at least $4.94' »

Consensus $5.21. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NFLX

Netflix

$286.83

2.59 (0.91%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Recommendations
Netflix analyst commentary  »

KeyBanc lowers estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

NBRV

Nabriva Therapeutics

$2.01

0.08 (4.15%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Conference/Events
Nabriva Therapeutics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

BBIO

BridgeBio

$17.92

-0.6 (-3.24%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Hot Stocks
BridgeBio reports preclinical data on infigratinib in treating achondroplasia »

BridgeBio Pharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCBJY

UCB

$0.00

(0.00%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Hot Stocks
UCB says bimekizumab Phase 3 psoriasis study meets all endpoints »

UCB announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SASR

Sandy Spring Bancorp

$33.42

0.21 (0.63%)

07:04
10/17/19
10/17
07:04
10/17/19
07:04
Earnings
Sandy Spring Bancorp reports Q3 EPS 82c, consensus 80c »

"In the third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.